Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Deferred Tax Liability: 2022-2024

Historic Non-Current Deferred Tax Liability for Sunshine Biopharma (SBFM) over the last 3 years, with Dec 2024 value amounting to $389,513.

  • Sunshine Biopharma's Non-Current Deferred Tax Liability rose 72.74% to $389,513 in Q4 2024 from the same period last year, while for Dec 2024 it was $389,513, marking a year-over-year increase of 72.74%. This contributed to the annual value of $389,513 for FY2024, which is 72.74% up from last year.
  • Sunshine Biopharma's Non-Current Deferred Tax Liability amounted to $389,513 in FY2024, which was up 72.74% from $225,493 recorded in FY2023.
  • In the past 5 years, Sunshine Biopharma's Non-Current Deferred Tax Liability registered a high of $389,513 during FY2024, and its lowest value of $43,032 during FY2022.
  • For the 3-year period, Sunshine Biopharma's Non-Current Deferred Tax Liability averaged around $219,346, with its median value being $225,493 (2023).
  • Data for Sunshine Biopharma's Non-Current Deferred Tax Liability shows a peak YoY skyrocketed of 424.01% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Sunshine Biopharma's Non-Current Deferred Tax Liability stood at $43,032 in 2022, then surged by 424.01% to $225,493 in 2023, then spiked by 72.74% to $389,513 in 2024.